Biosergen secures Swedish regulatory clearance for merger with Flerie
The Swedish Companies Registration Office has cleared implementation of the merger between Flerie and Biosergen. Registration is expected October 23, 2026, dissolving the company and transferring all its assets and liabilities to Flerie. The business will move to a newly formed subsidiary of Flerie Invest, a wholly owned Flerie subsidiary. Shareholders will receive one newly issued Flerie ordinary share per 31 shares held, with delivery expected around October 28, 2026. Delisting from Nasdaq First North Growth Market will follow, with the last trading day expected October 22, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biosergen AB published the original content used to generate this news brief via Cision (Ref. ID: 20261016:BIT:4583:0) on October 16, 2026, and is solely responsible for the information contained therein. (C)
The Swedish Companies Registration Office has cleared implementation of the merger between Flerie and Biosergen. Registration is expected October 23, 2026, dissolving the company and transferring all its assets and liabilities to Flerie. The business will move to a newly formed subsidiary of Flerie Invest, a wholly owned Flerie subsidiary. Shareholders will receive one newly issued Flerie ordinary share per 31 shares held, with delivery expected around October 28, 2026.
Delisting from Nasdaq First North Growth Market will follow, with the last trading day expected October 22, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biosergen AB published the original content used to generate this news brief via Cision (Ref.
ID: 20261016:BIT:4583:0) on October 16, 2026, and is solely responsible for the information contained therein. (C)